Vivos Therapeutics, Inc. (NASDAQ:VVOS) Short Interest Update

Posted by on Sep 14th, 2026

Vivos Therapeutics, Inc. (NASDAQ:VVOS – Get Free Report) saw a significant increase in short interest in August. As of August 31st, there was short interest totaling 2,503,479 shares, an increase of 100.4% from the August 15th total of 1,249,260 shares. Based on an average daily trading volume, of 49,532,777 shares, the short-interest ratio is currently 0.1 days. Approximately 18.4% of the company’s shares are sold short.

Vivos Therapeutics Stock Down 4.3%

Shares of NASDAQ VVOS traded down $0.01 during trading on Monday, reaching $0.18. The company had a trading volume of 902,926 shares, compared to its average volume of 4,703,563. The business’s 50-day moving average is $0.33 and its 200 day moving average is $0.71. Vivos Therapeutics has a 12-month low of $0.16 and a 12-month high of $3.70. The stock has a market cap of $2.45 million, a PE ratio of -0.09 and a beta of 6.04.

Vivos Therapeutics (NASDAQ:VVOS – Get Free Report) last released its earnings results on Friday, August 14th. The company reported ($0.31) earnings per share for the quarter, beating the consensus estimate of ($0.41) by $0.10. The company had revenue of $5.15 million for the quarter, compared to the consensus estimate of $5.63 million. Vivos Therapeutics had a negative return on equity of 2,325.64% and a negative net margin of 122.00%. On average, analysts anticipate that Vivos Therapeutics will post -1.54 earnings per share for the current year.

Institutional Investors Weigh In On Vivos Therapeutics

Large investors have recently bought and sold shares of the company. XTX Topco Ltd purchased a new stake in Vivos Therapeutics in the second quarter valued at $65,000. B. Riley Wealth Advisors Inc. purchased a new position in Vivos Therapeutics during the second quarter valued at approximately $220,000. Connective Capital Management LLC acquired a new position in Vivos Therapeutics in the third quarter valued at approximately $620,000. Acorn Wealth Advisors LLC purchased a new stake in Vivos Therapeutics in the 4th quarter worth approximately $30,000. Finally, DRW Securities LLC grew its stake in shares of Vivos Therapeutics by 179.5% during the 4th quarter. DRW Securities LLC now owns 115,907 shares of the company’s stock worth $235,000 after purchasing an additional 74,441 shares during the period. Hedge funds and other institutional investors own 26.35% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have weighed in on VVOS shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Vivos Therapeutics in a research report on Friday, July 17th. Ascendiant Capital Markets raised their target price on Vivos Therapeutics from $3.00 to $3.10 and gave the company a “buy” rating in a research note on Thursday, June 4th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $2.80.

View Our Latest Stock Report on VVOS

About Vivos Therapeutics

(Get Free Report)

Vivos Therapeutics, Inc is a medical technology company focused on the development and commercialization of oral appliance therapy for the treatment of obstructive sleep apnea (OSA) and other airway-related disorders. The company’s proprietary Vivos System integrates clinical diagnostic protocols, three-dimensional imaging, and custom-designed dental appliances to address mild to moderate forms of sleep-disordered breathing through non-surgical, non-invasive means.

The Vivos System comprises a range of custom oral devices, digital workflow tools, and a structured treatment protocol.

Featured Articles

Receive News & Ratings for Vivos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.